Company profile
Redbiotec AG
Redbiotec develops therapeutic bacteria to treat cancer and genetic disorders. Designed to overcome delivery hurdles faced by other vehicles, the proprietary bacteria platform accommodates large and diverse therapeutic cargos ranging from oncolytic virus to gene editing system. The company builds upon its teams expertise in microbial engineering and immunology. During its era as a vaccine innovator, Redbiotec has sold its CMV vaccine business to Pfizer in 2015 and also created an HSV-2 immunotherapy.
Source: startup.ch
Highlights
Top 100 Swiss Startup Award 2011
The new Swiss Venture Capital Report was published on 26 January. It analyses 304 financing rounds closed in 2020 and includes further article such as an interview with Michael Hengartner, President of the ETH Board, and a list of Swiss "soonicorns". 
